Flame Biosciences is a NYC-based clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics for diseases linked to chronic inflammation. Led by CEO and co‑founder Harlan Weisman, MD, the company is developing monoclonal antibodies that bind and neutralize interleukin‑1β (IL‑1β), with FL‑101 as its lead candidate. FL‑101 is intended to treat multiple diseases, most notably cancer, based on preclinical models and clinical data implicating IL‑1β in tumor‑promoting inflammation and the tumor microenvironment. Flame believes FL‑101 has potential best‑in‑class attributes and plans to enter the clinic in the first half of 2021 for proof‑of‑concept testing in patients with non‑small cell lung cancer. The company completed a $100M common stock financing and will use proceeds to progress clinical trials and secure additional business development opportunities. Flame’s broader pipeline and development plans target conditions such as atherosclerotic cardiovascular disease and arthritis that are linked to chronic inflammation.

Total raised

$100M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2020